Nurix therapeutics reports fourth quarter and fiscal year 2020 financial results and provides a corporate update

First investigational new drug (ind) application cleared for nx-2127 in patients with relapsed and refractory b-cell malignancies

NRIX Ratings Summary

NRIX Quant Ranking